AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26036212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=5409)
Number of subjects: 10739
Study 25287554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Number of subjects: 30
Study 25287554 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 30
Study 25287554 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct stimulation
Number of subjects: 30
Study 25287554 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG biofeedback
Number of subjects: 30
Study 25287554 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 30
Study 22843170 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy with sulphurous thermal water (20 min per occasion, 15 times over 3 weeks)
Number of subjects: 47
Study 22843170 — intervention group
Group type: COMPARATOR
Intervention: Warm tap water (control group)
Number of subjects: 47
Study 22843170 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy with sulphurous thermal water
Number of subjects: 47
Study 20127540 — intervention group
Group type: COMPARATOR
Intervention: Emotion suppression
Number of subjects: 34
Study 20127540 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion allowance
Number of subjects: 34
Study 17650793 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Ginkgo biloba (EGb) given additionally to routine treatment for 2 months.
Number of subjects: 63
Study 17650793 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (control group).
Number of subjects: 63
Study 16081619 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged electrical muscle stimulation (EMS)
Number of subjects: 15
Study 12105833 — intervention group
Group type: EXPERIMENTAL
Intervention: 15N soy protein
Number of subjects: 13
Study 12105833 — intervention group
Group type: COMPARATOR
Intervention: 15N milk protein
Number of subjects: 13
Study 9921569 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery audiotape listened to once a day for the duration of the study
Number of subjects: 53
Study 9921569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guided imagery intervention)
Number of subjects: 53
Study 8804449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography screening
Number of subjects: 2025
Study 8804449 — intervention group
Group type: COMPARATOR
Intervention: Repeat sonography
Number of subjects: 2025
Study 2500070 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK (oral) in addition to mitomycin C and 5-FU for over 3 years
Number of subjects: 462
Study 2500070 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C intravenously and 5-FU orally for 6 months
Number of subjects: 462
Study 5306538 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of cholera vaccine
Number of subjects: 40000
Study 5306538 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of cholera vaccine at an interval of 1 month
Number of subjects: 40000
Study 5306538 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of cholera vaccine
Number of subjects: 40000
Study 31017492 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether emulsion (1%)
Number of subjects: 130
Study 31017492 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole emulsion (3%)
Number of subjects: 130
Study 28679471 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically assisted selective neck dissection (SND)
Number of subjects: 60
Study 28679471 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 60
Study 25346994 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of Day (TOD)
Number of subjects: 0
Study 25346994 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake controlled
Number of subjects: 0
Study 22964356 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (1.2 mmol/L)
Number of subjects: 60
Study 22964356 — intervention group
Group type: COMPARATOR
Intervention: Hyperkalemic cardioplegia
Number of subjects: 60
Study 21691245 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sanitizer and respiratory hygiene education in intervention schools
Number of subjects: 3360
Study 21691245 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3360
Study 18205730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group consuming high amounts of six selected vegetables (target of 350 g/day for 65 days)
Number of subjects: 94
Study 18205730 — intervention group
Group type: COMPARATOR
Intervention: Control group avoiding the same six vegetables
Number of subjects: 94
Study 18205730 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 94
Study 21629359 — intervention group
Group type: COMPARATOR
Intervention: Negative expiratory pressure (NEP) at -5 cm H(2)O, seated
Number of subjects: 60
Study 21629359 — intervention group
Group type: COMPARATOR
Intervention: Negative expiratory pressure (NEP) at -10 cm H(2)O, seated
Number of subjects: 60
Study 21629359 — intervention group
Group type: COMPARATOR
Intervention: Negative expiratory pressure (NEP) at -5 cm H(2)O, supine
Number of subjects: 60
Study 21629359 — intervention group
Group type: COMPARATOR
Intervention: Negative expiratory pressure (NEP) at -10 cm H(2)O, supine
Number of subjects: 60
Study 21629359 — intervention group
Group type: COMPARATOR
Intervention: Negative expiratory pressure (NEP)
Number of subjects: 60
Study 16415629 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality therapy program
Number of subjects: 30
Study 16415629 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 12477679 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide in O2
Number of subjects: 54
Study 12477679 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen (control group)
Number of subjects: 54
Study 9648959 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 microg b.d.
Number of subjects: 49
Study 9648959 — intervention group
Group type: COMPARATOR
Intervention: placebo b.d.
Number of subjects: 49
Study 8018374 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (31.5 Gy in 18 fractions)
Number of subjects: 0
Study 2491075 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 17
Study 2491075 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 17
Study 11204290 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 11
Study 11204290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30877638 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home intervention providing strategies to manage behavioral symptoms and caregiver stress, 8 sessions over 3 months.
Number of subjects: 226
Study 30877638 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home intervention (indirectly through time spent assisting PwD).
Number of subjects: 226
Study 30403756 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month lifestyle intervention program
Number of subjects: 577
Study 27358210 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 145
Study 27358210 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 145
Study 27358210 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg and 140 mg
Number of subjects: 145
Study 25298573 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata (125 mg, 2 capsules)
Number of subjects: 12
Study 25298573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22616314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed ratio of morphine and oxycodone combinations (MOX) at ratios 3:2 in study A and 1:2 in study B
Number of subjects: 0
Study 22616314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed ratio of morphine and oxycodone combinations (MOX)
Number of subjects: 0
Study 22616314 — intervention group
Group type: COMPARATOR
Intervention: Morphine monotherapy
Number of subjects: 0
Study 20529365 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-page survey
Number of subjects: 780
Study 20529365 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-page survey
Number of subjects: 780
Study 20529365 — intervention group
Group type: COMPARATOR
Intervention: Letter pre-notification
Number of subjects: 780
Study 20529365 — intervention group
Group type: COMPARATOR
Intervention: Postcard pre-notification
Number of subjects: 780
Study 20529365 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-page survey for individuals in their 20s
Number of subjects: 780
Study 20529365 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-page survey for individuals in their 20s
Number of subjects: 780
Study 20529365 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-page survey for individuals in their 30s
Number of subjects: 780
Study 20529365 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-page survey for individuals in their 30s
Number of subjects: 780
Study 17589281 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral therapy plus sibutramine
Number of subjects: 79
Study 17589281 — intervention group
Group type: COMPARATOR
Intervention: Family-based behavioral therapy plus placebo
Number of subjects: 79
Study 17589281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (regardless of intervention)
Number of subjects: 79
Study 17589281 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral therapy plus sibutramine (Caucasian group)
Number of subjects: 79
Study 17589281 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral therapy plus sibutramine (African American group)
Number of subjects: 79
Study 15114376 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based low-fat diet with flexible fat content (20% or 15% of energy as fat)
Number of subjects: 32
Study 15114376 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based low-fat diet with flexible fat content
Number of subjects: 32
Study 15114376 — intervention group
Group type: COMPARATOR
Intervention: Control group consuming a plant-based low-fat diet with 20% of energy as fat
Number of subjects: 32
Study 11880813 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (P)
Number of subjects: 0
Study 11880813 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (S)
Number of subjects: 0
Study 11880813 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of power and stretch training (PS)
Number of subjects: 0
Study 11880813 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study 9813560 — intervention group
Group type: EXPERIMENTAL
Intervention: GSNO 10(‐6) M (in vitro)
Number of subjects: 24
Study 9813560 — intervention group
Group type: EXPERIMENTAL
Intervention: GSNO (40 nmol/min) (in vivo)
Number of subjects: 24
Study 8132135 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (3 x 100 micrograms/day s.c.)
Number of subjects: 0
Study 8132135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2592583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 8
Study 2592583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4467872 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate tablets, BP, given before meals
Number of subjects: 0
Study 4467872 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate tablets, BP, given after meals
Number of subjects: 0
Study 4467872 — intervention group
Group type: COMPARATOR
Intervention: Sustained release formulation of ferrous salts
Number of subjects: 0
Study 4467872 — intervention group
Group type: COMPARATOR
Intervention: Other ferrous salts
Number of subjects: 0
Study 4467872 — intervention group
Group type: COMPARATOR
Intervention: Liquid iron preparation
Number of subjects: 0
Study 29804376 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Number of subjects: 106
Study 29804376 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil
Number of subjects: 106
Study 28245911 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS)
Number of subjects: 70
Study 28245911 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (ACT)
Number of subjects: 70
Study 25901427 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Placebo
Number of subjects: 1103
Study 25901427 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone-Placebo
Number of subjects: 1103
Study 25901427 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline-Placebo
Number of subjects: 1103
Study 25901427 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone-Pentoxifylline
Number of subjects: 1103
Study 25901427 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 1103
Study 25901427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 1103
Study 25901427 — intervention group
Group type: COMPARATOR
Intervention: No Prednisolone
Number of subjects: 1103
Study 24008808 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol fixed combination
Number of subjects: 90
Study 24008808 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 90
Study 24008808 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 90
Study 21498674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 500 mg
Number of subjects: 61
Study 21498674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg
Number of subjects: 61
Study 21498674 — intervention group
Group type: EXPERIMENTAL
Intervention: O-FC (both doses)
Number of subjects: 61
Study 19080708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar plexus block (Group A)
Number of subjects: 60
Study 19080708 — intervention group
Group type: COMPARATOR
Intervention: Epidural block (Group B)
Number of subjects: 60
Study 19080708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 15982795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit teas (various types)
Number of subjects: 0
Study 15982795 — intervention group
Group type: COMPARATOR
Intervention: 0.2% citric acid solution (positive control)
Number of subjects: 0
Study 12818970 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal treatment with mupirocin
Number of subjects: 60
Study 12818970 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (control group)
Number of subjects: 60
Study 10977438 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin
Number of subjects: 211
Study 10977438 — intervention group
Group type: COMPARATOR
Intervention: Oral cefuroxime axetil
Number of subjects: 211
Study 8875535 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN supplemented with 10 mg of iron as iron dextran daily (group 2)
Number of subjects: 23
Study 8875535 — intervention group
Group type: COMPARATOR
Intervention: TPN without iron (group 1)
Number of subjects: 23
Study 8875535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 1671884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditiocarb sodium (400 mg/m2 orally for 24 weeks)
Number of subjects: 389
Study 1671884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 1671884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditiocarb sodium
Number of subjects: 389
Study 6558741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime story tape recorded by the parent
Number of subjects: 18
Study 6558741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bedtime story)
Number of subjects: 18
Study 31825025 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive flash-free (FF) brackets
Number of subjects: 50
Study 31825025 — intervention group
Group type: COMPARATOR
Intervention: Adhesive pre-coated (APC) brackets
Number of subjects: 50
Study 29576447 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support for breastfeeding (weekly for 2 months, then every 2 weeks until 6 months)
Number of subjects: 380
Study 29576447 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 380
Study 29576447 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support for breastfeeding
Number of subjects: 380
Study 26851398 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant (180 mg)
Number of subjects: 0
Study 26851398 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 24472061 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected LV lead position using standard fluoroscopy systems
Number of subjects: 16
Study 24472061 — intervention group
Group type: COMPARATOR
Intervention: Validation group (n = 8)
Number of subjects: 16
Study 24472061 — intervention group
Group type: EXPERIMENTAL
Intervention: Application group (n = 8)
Number of subjects: 16
Study 23235967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography plus KUB assessment
Number of subjects: 139
Study 23235967 — intervention group
Group type: COMPARATOR
Intervention: Intravenous urography (IVU)
Number of subjects: 139
Study 20659762 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin daily for two months
Number of subjects: 32
Study 20659762 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin daily for two months
Number of subjects: 32
Study 20659762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic ASA therapy
Number of subjects: 32
Study 20659762 — intervention group
Group type: COMPARATOR
Intervention: All patients
Number of subjects: 32
Study 20659762 — intervention group
Group type: COMPARATOR
Intervention: Brachial artery endothelial function via flow‐mediated dilation (BAFMD)
Number of subjects: 32
Study 17986845 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and 5‐fluorouracil
Number of subjects: 476
Study 17986845 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy and gemcitabine
Number of subjects: 476
Study 15855578 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nateglinide
Number of subjects: 108
Study 15855578 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nateglinide
Number of subjects: 108
Study 15855578 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg nateglinide
Number of subjects: 108
Study 15855578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 11923801 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg
Number of subjects: 193
Study 11923801 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg
Number of subjects: 193
Study 11923801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Azimilide (100 and 125 mg)
Number of subjects: 193
Study 11923801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 10615220 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsley intervention (3.73‐4.49 mg apigenin/MJ)
Number of subjects: 14
Study 10615220 — intervention group
Group type: COMPARATOR
Intervention: Basic diet (control)
Number of subjects: 14
Study 10615220 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsley intervention
Number of subjects: 14
Study 7793179 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.0‐1.5 mg kg‐1
Number of subjects: 1247
Study 7793179 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine in patients with newly discovered genotypes AK (5 patients) and AH (1 patient)
Number of subjects: 1247
Study 1790064 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 109
Study 1790064 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 109
Study 6127968 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg
Number of subjects: 2
Study 6127968 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.15 mg/kg
Number of subjects: 2
Study 30371644 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention
Number of subjects: 82
Study 30371644 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 82
Study 26756278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs) combined with home exercise program (HEP)
Number of subjects: 31
Study 26756278 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (HEP) alone
Number of subjects: 31
Study 24713402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 85
Study 24713402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 85
Study 24713402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 85
Study 24713402 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐β1a
Number of subjects: 85
Study 21982202 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 52
Study 21982202 — intervention group
Group type: COMPARATOR
Intervention: Simulation group (control)
Number of subjects: 52
Study 20109071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 100 mg BID
Number of subjects: 42
Study 20109071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg BID
Number of subjects: 42
Study 20109071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg BID
Number of subjects: 42
Study 20109071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 300 mg continuous
Number of subjects: 42
Study 20109071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg continuous
Number of subjects: 42
Study 20109071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (any schedule)
Number of subjects: 42
Study 18817605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg.day) for 3 days
Number of subjects: 43
Study 18817605 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 43
Study 16525179 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant or adjuvant procarbazine, lomustine, and vincristine (PCV) added to radiotherapy
Number of subjects: 0
Study 16525179 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 15311643 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic levels drawn from a central venous catheter (CVC)
Number of subjects: 0